Inovio Pharmaceuticals Inc
General ticker "INO" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $97.7M
Inovio Pharmaceuticals Inc does not follow the US Stock Market performance with the rate: -16.2%.
Estimated limits based on current volatility of 3.3%: low 1.69$, high 1.91$
Factors to consider:
- Company does not operate outside North America (retrieved using AI)
- Current price 52.6% below estimated low
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [3.88$, 10.82$]
- 2024-12-30 to 2025-12-30 estimated range: [4.43$, 11.46$]
Financial Metrics affecting the INO estimates:
- Negative: Non-GAAP EPS, $ of -7.08 <= 0.10
- Negative: Operating profit margin, % of -99.43 <= 1.03
- Negative: Operating cash flow per share per price, % of -54.10 <= 2.35
- Negative: negative Net income
- Negative: Industry operating cash flow per share per price (median), % of -23.87 <= 3.85
- Positive: Inventory ratio change, % of 0 <= 0
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term INO quotes
Long-term INO plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $1.77MM | $10.26MM | $0.83MM |
| Operating Expenses | $302.99MM | $277.84MM | $144.77MM |
| Operating Income | $-301.22MM | $-267.57MM | $-143.94MM |
| Non-Operating Income | $-2.01MM | $-10.08MM | $8.82MM |
| Interest Expense | $1.94MM | $1.25MM | $1.22MM |
| R&D Expense | $249.24MM | $187.65MM | $86.68MM |
| Income(Loss) | $-303.22MM | $-277.65MM | $-135.12MM |
| Other Income(Loss) | $0.00MM | $-2.17MM | $0.00MM |
| Profit(Loss) | $-303.22MM | $-279.82MM | $-135.12MM |
| Stockholders Equity | $399.67MM | $222.36MM | $117.35MM |
| Assets | $495.94MM | $348.53MM | $170.95MM |
| Operating Cash Flow | $-215.71MM | $-216.22MM | $-124.37MM |
| Capital expenditure | $1.23MM | $0.97MM | $0.32MM |
| Investing Cash Flow | $-175.34MM | $109.59MM | $87.36MM |
| Financing Cash Flow | $211.50MM | $81.84MM | $5.00MM |
| Earnings Per Share* | $-17.55 | $-14.47 | $-6.09 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.